Wockhardt Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vswx79mpjws5awvizvw91d93.pdf

Key Takeaways


The Zaynich Opportunity & US Launch

Habil Khorakiwala: "I establish an organization and we continue. Second biggest advantage people don't recognize, that if you're committed 100% to a cause, which we are, we'll do a better job in penetrating the market than a partner who is distracted with half a dozen products."

India & Emerging Markets: An Access-First Blueprint

Habil Khorakiwala: "So, from that point, whatever pre-launch activity people do to get off the ground, which we will have to do in US, but in India it is done. So, we expect Annapurna and the team to start hitting sixes from the day one."

Pipeline & Long-Term Growth Runway

Habil Khorakiwala: "We do not have a challenge in terms of growth for next 10 to 20 years. We don't need to acquire anything, excepting we can revisit the research or some other part. I don't need to acquire anything for growth. The growth is inherent in the organization because we have a series of molecules."

Core Business: The Funding Engine


Financial Commitments & The Near-Term Trade-Off

Murtaza Khorakiwala: "For many years, investors asked us when the investment in research, biotech, and innovation would begin to translate into growth. We believe that moment has arrived."

Guidance & Commitments

CommitmentSpecificsTimeline
Zaynich US and India launchStrategy execution and commercial launch in both marketsCurrent year (FY27)
Zaynich business breakevenBottom-line breakeven for the Zaynich business12–18 months from launch
European approvalSubmitted, approval expectedBy end of current year
Emerging market launchesLaunch in 7–8 high carbapenem-resistance marketsNext 18–24 months
Biosimilar capacity and business doublingDouble manufacturing capacity, then double the businessCapacity in 12–15 months; business in 24–36 months
Biosimilar pipeline launchesLaunch next wave of pipeline products (Aspart, Degludec, etc.)After two years
CapexNormal capex of INR200–300 crores annuallyNext three years
R&D focusAntibiotic research only, no expansion into chronic therapiesNext 10 years

Key Metrics

MetricQ4 FY26
Revenue₹3,373 cr
EBITDA₹630 cr, growth of about 51%
EBITDA margin18.6%, up from 5.4% three years ago
Profit before tax₹238 cr
Cash and equivalents₹662 cr
Net debt-to-equity ratio0.1
Biosimilar business growth27% (FY26)
Emerging markets revenue share28% of turnover, growing at 35%
UK revenue share39% of total business, growing at 13%
UK covered market share18%
Specialty business share23% of total business (biosimilars and novel antibiotic)
Zaynich global peak sales expectation$1.5 bn to $2 bn per year
Zaynich US daily cost$1,200 to $1,500 per day, treatment course about $10,000–$15,000
Zaynich India pricing discount vs US75% to 80% discount to US pricing
Zaynich Phase 3 composite cure rate96.8%, clinical and micro cure rate about 89–90%, 20% higher than Meropenem
Zaynich compassionate use patients85 across India, US, Malaysia, and France
Zaynich patent expiry2038, with additional patents being filed to extend beyond
Biosimilar pipeline products5 in development (Aspart, RN 30/70, Degludec, Degludec Aspart, Semaglutide)
Biosimilar emerging market registrations30 emerging markets
Normal capex next three years₹200 cr to ₹300 cr
R&D investment over last 25 years$800 mn
Zaynich first 12–18 months profitability impactMinor loss or neutral for the Zaynich business specifically
Long-term resistant-case market share target20% to 25% globally, potentially higher in India
cUTI re-admission rate20% to 25%
Gram-negative hospital infections in US0.12 cr (0.12 crore)
cUTI indication size in US600,000
HAP/VAP indication size in US290,000
India gram-negative infection burden600,000 to 700,000 patients, 35% to 45% with carbapenem resistance
Empirical treatment failure rate in high-burden settings40%
Multi-pathogen infection share15% to 25%
Elderly hospitalization risk vs general3x to 5x higher for patients 65+
Human insulin production scale-up2x
Glargine production scale-up1.5x
Biosimilar business doubling timeline24 to 36 months
Biosimilar capacity doubling timeline12 to 15 months
UK subscription model valueGBP 2 cr per year for three years, fixed irrespective of supply value
QIDP exclusivity extension5 years additional exclusivity granted by US FDA
Minimum exclusivity in US/western markets10 years irrespective of patent expiry
Miqnaf patent expiry in IndiaEarly 2033
US anti-infective use outside hospital35% to 40%
All new US anti-infective drugs collective marketAbout $1 bn today
New anti-infectives first three-year collective revenue$30 cr to $50 cr (per an analyst's math)
ID specialists in India300